Ligand-dependent mechanisms of sst2A receptor trafficking: Role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists

Molecular Endocrinology

Volumn 25, Issue 6, 2011, Pages 1040-1054

  Kao, Yachu J ^a   Ghosh, Madhumita ^a   Schonbrunn, Agnes ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KE 108; PASIREOTIDE; RECEPTOR PROTEIN; RETINA S ANTIGEN; SOMATOSTATIN 14; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR SUBTYPE 2A; TYROSINE CYCLO (DEXTRO DIAMINOBUTYRIC ACID ARGINYLPHENYLALANYLPHENYLALANYL DEXTRO TRYTOPHANYLLYSYLTHREONYLPHENYLALANINE); UNCLASSIFIED DRUG;

ACINAR CELL; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DEPHOSPHORYLATION; DRUG EFFECT; DRUG HALF LIFE; ENDOCYTOSIS; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

ANIMALS; ARRESTINS; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; ENDOCYTOSIS; PANCREAS, EXOCRINE; PEPTIDES, CYCLIC; PHOSPHORYLATION; PROTEIN TRANSPORT; RATS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 79957663678     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2010-0398     Document Type: Article

References (46)

1. Reubi JC, Maecke HR 2008 Peptide-based probes for cancer imaging. J Nucl Med 49:1735-1738
2. Colao A, Faggiano A, Pivonello R 2010 Somatostatin analogues: treatment of pituitary and neuroendocrine tumors. Prog Brain Res 182:281-294
3. De Martino MC, Hofland LJ, Lamberts SW 2010 Somatostatin and somatostatin receptors: from basic concepts to clinical applications. Prog Brain Res 182:255-280
4. Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW, Krenning EP 2010 Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 17:R53-R73
5. Modlin IM, Pavel M, Kidd M, Gustafsson BI 2010 Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 31: 169-188
6. Schonbrunn A 2004 Somatostatin receptors. In: Lennarz WJ, Lane MD, eds. Encyclopedia of biological chemistry. Oxford: Elsevier; 55-60
7. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707-716
8. Reubi JC, Eisenwiener KP, Rink H, Waser B, Mäcke HR 2002 A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Eur J Pharmacol 456:45-49
9. Schmid HA, Schoeffter P 2004 Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80(Suppl 1):47-50
10. Liu Q, Cescato R, Dewi DA, Rivier J, Reubi JC, Schonbrunn A 2005 Receptor signaling and endocytosis are differentially regulated by somatostatin analogs. Mol Pharmacol 68:90-101
11. Cervia D, Langenegger D, Schuepbach E, Cammalleri M, Schoeffter P, Schmid HA, Bagnoli P, Hoyer D 2005 Binding and functional properties of the novel somatostatin analogue KE 108 at native mouse somatostatin receptors. Neuropharmacology 48:881-893
12. Cescato R, Loesch KA, Waser B, Mäcke HR, Rivier JE, Reubi JC, Schonbrunn A 2010 Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways. Mol Endocrinol 24:240-249
13. Elberg G, Hipkin RW, Schonbrunn A 2002 Homologous and heterologous regulation of somatostatin receptor 2. Mol Endocrinol 16:2502-2514
14. Kenakin T, Miller LJ 2010 Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62: 265-304
15. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB 2007 Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13
16. Kenakin T 2008 Functional assays as prismatic views of drug activity: relevance to new drug discovery. J Recept Signal Transduct Res 28:109-125
17. Mailman RB 2007 GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 28:390-396
18. Schonbrunn A 2008 Selective agonism in somatostatin receptor signaling and regulation. Mol Cell Endocrinol 286:35-39
19. Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S 2009 Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab 94:654-661
20. Hipkin RW, Friedman J, Clark RB, Eppler CM, Schonbrunn A 1997 Agonist-induced desensitization, internalization, and phosphorylation of the sst2a somatostatin receptor. J Biol Chem 272: 13869-13876
21. Liu Q, Bee MS, Schonbrunn A 2009 Site specificity of agonist and second messenger-activated kinases for somatostatin receptor subtype 2A (sst2A) phosphorylation. Mol Pharmacol 76:68-80
22. Liu Q, Reubi JC, Wang Y, Knoll BJ, Schonbrunn A 2003 In vivo phosphorylation of the somatostatin 2A receptor in human tumors. J Clin Endocrinol Metab 88:6073-6079
23. Liu Q, Dewi DA, Liu W, Bee MS, Schonbrunn A 2008 Distinct phosphorylation sites in the SST2A somatostatin receptor control internalization, desensitization, and arrestin binding. Mol Pharmacol 73:292-304
24. Hipkin RW, Wang Y, Schonbrunn A 2000 Protein kinase C activation stimulates the phosphorylation and internalization of the sst2A somatostatin receptor. J Biol Chem 275:5591-5599
25. Moore CA, Milano SK, Benovic JL 2007 Regulation of receptor trafficking by GRKs and arrestins. Annu Rev Physiol 69:451-482
26. Luttrell LM, Gesty-Palmer D 2010 Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol Rev 62:305-330
27. Krasel C, Bünemann M, Lorenz K, Lohse MJ 2005 β-Arrestin binding to the β2-adrenergic receptor requires both receptor phosphorylation and receptor activation. J Biol Chem 280: 9528-9535
28. Tran TM, Friedman J, Baameur F, Knoll BJ, Moore RH, Clark RB 2007 Characterization of β2-adrenergic receptor dephosphorylation: comparison with the rate of resensitization. Mol Pharmacol 71:47-60
29. Sorkin A, von Zastrow M 2009 Endocytosis and signalling: intertwining molecular networks. Nat Rev Mol Cell Biol 10:609-622
30. Calebiro D, Nikolaev VO, Persani L, Lohse MJ 2010 Signaling by internalized G-protein-coupled receptors. Trends Pharmacol Sci 31:221-228
31. Waser B, Cescato R, Tamma ML, Maecke HR, Reubi JC 2010 Absence of somatostatin SST(2) receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model. Eur J Pharmacol 644:257-262
32. Tobin AB 2008 G-protein-coupled receptor phosphorylation: where, when and by whom. Br J Pharmacol 153(Suppl 1):S167-S176
33. Zidar DA, Violin JD, Whalen EJ, Lefkowitz RJ 2009 Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc Natl Acad Sci USA 106: 9649-9654
34. Busillo JM, Armando S, Sengupta R, Meucci O, Bouvier M, Benovic JL 2010 Site specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. J Biol Chem 285:7805-7817
35. Pöll F, Lehmann D, Illing S, Ginj M, Jacobs S, Lupp A, Stumm R, Schulz S 2010 Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. Mol Endocrinol 24:436-446
36. Oakley RH, Laporte SA, Holt JA, Caron MG, Barak LS 2000 Differential affinities of visual arrestin, β arrestin1, and β arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 275:17201-17210
37. Gurevich VV, Gurevich EV 2006 The structural basis of arrestinmediated regulation of G-protein-coupled receptors. Pharmacol Ther 110:465-502
38. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK 2007 β-Arrestins and cell signaling. Annu Rev Physiol 69:483-510
39. Xiao K, Sun J, Kim J, Rajagopal S, Zhai B, Villén J, Haas W, Kovacs JJ, Shukla AK, Hara MR, Hernandez M, Lachmann A, Zhao S, Lin Y, Cheng Y, Mizuno K, Ma'ayan A, Gygi SP, Lefkowitz RJ 2010 Global phosphorylation analysis of β-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci USA 107:15299-15304
40. Gurevich VV, Gurevich EV, Cleghorn WM 2008 Arrestins as multifunctional signaling adaptors. Handb Exp Pharmacol 15-37
41. Rajagopal S, Rajagopal K, Lefkowitz RJ 2010 Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 9:373-386
42. Koenig JA, Edwardson JM 1997 Endocytosis and recycling of G protein-coupled receptors. Trends Pharmacol Sci 18:276-287
43. Weckbecker G, Briner U, Lewis I, Bruns C 2002 SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 143:4123-4130
44. Rajeswaran WG, Hocart SJ, Murphy WA, Taylor JE, Coy DH 2001 Highly potent and subtype selective ligands derived by N-methyl scan of a somatostatin antagonist. J Med Chem 44:1305-1311
45. Huttenrauch F, Nitzki A, Lin FT, Höning S, Oppermann M 2002 β-Arrestin binding to chemokine receptor CCR5 requires multiple C-terminal receptor phosphorylation sites and involves a conserved Asp-Arg-Tyr sequence motif. J Biol Chem 277:30769-30777
46. Ghosh M, Schonbrunn A 2011 Differential temporal and spatial regulation of somatostatin receptor phosphorylation and dephosphorylation. J Biol Chem 286:13561-13573